Podcast: Michael Kamarck of Merck BioVentures on Opportunities in Biosimilars - - BioPharm International

ADVERTISEMENT

Podcast: Michael Kamarck of Merck BioVentures on Opportunities in Biosimilars


Michael Kamarck, President, Merck BioVentures Opportunities in Biosimilars

With the approval of an abbreviated pathway by which biosimilars may be authorized in the US, the attention is now shifting to the challenges in store for innovator companies in defending their patents and the generics companies in challenging them. In this interview, Michael Kamarck, president of Merck BioVentures and senior vice president, vaccines and biologics manufacturing, discusses the opportunities and challenges in biosimilars.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines

Click here